ALLIANCE PHARMA PLC has announced a delay in the publication of its preliminary results for 2023, now expected to be released on 23 April 2024. The delay is due to the volume of work required to complete the audit exceeding original expectations. The company has confirmed that the details provided in the full year trading update on 29 January 2024 remain accurate. A meeting for analysts will be held on the day of the results, and a live webcast of the meeting will be available on the Alliance website, with a replay to follow. The company's purpose is to empower people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. ALLIANCE PHARMA PLC is a growing consumer healthcare company, with a focus on organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. The Group employs around 285 people across Europe, North America, and the Asia Pacific region and remains asset-light by outsourcing manufacturing and logistics.